/주식/ALKS
ALKS

ALKS

USD

Alkermes plc Ordinary Shares

$30.480+0.480 (1.600%)

실시간 가격

Healthcare
Drug Manufacturers - Specialty & Generic
아일랜드

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$30.000

고가

$30.630

저가

$29.770

거래량

0.42M

기업 기본 정보

시가총액

5.0B

산업

Drug Manufacturers - Specialty & Generic

국가

Ireland

거래 통계

평균 거래량

2.00M

거래소

NMS

통화

USD

52주 범위

저가 $25.17현재가 $30.480고가 $36.45

관련 뉴스

Analyst Upgrades

Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42

Wells Fargo analyst Benjamin Burnett maintains Alkermes with a Overweight and lowers the price target from $44 to $42.

더 보기
Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42
Analyst Upgrades

Needham Maintains Buy on Alkermes, Raises Price Target to $44

Needham analyst Ami Fadia maintains Alkermes with a Buy and raises the price target from $43 to $44.

더 보기
Needham Maintains Buy on Alkermes, Raises Price Target to $44
PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving ...

더 보기
Alkermes plc Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45

Mizuho analyst Uy Ear maintains Alkermes with a Outperform and raises the price target from $40 to $45.

더 보기
Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45
Analyst Upgrades

Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45

Piper Sandler analyst David Amsellem reiterates Alkermes with a Overweight and raises the price target from $38 to $45.

더 보기
Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45
Analyst Upgrades

RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $47

RBC Capital analyst Leonid Timashev maintains Alkermes with a Outperform and raises the price target from $45 to $47.